Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $7.86 Analyst target: $13.93 Upside: 77.23%
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
See the full interactive analysis & chart →Informational only — not investment advice.